EntryPoint Capital LLC Acquires Shares of 44,458 MaxCyte, Inc. (NASDAQ:MXCT)

EntryPoint Capital LLC acquired a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 44,458 shares of the company’s stock, valued at approximately $185,000.

Several other hedge funds and other institutional investors also recently modified their holdings of MXCT. River Global Investors LLP lifted its holdings in shares of MaxCyte by 57.7% during the fourth quarter. River Global Investors LLP now owns 3,253,192 shares of the company’s stock worth $13,494,000 after purchasing an additional 1,190,630 shares during the period. Geode Capital Management LLC raised its position in MaxCyte by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,474,632 shares of the company’s stock worth $9,628,000 after buying an additional 47,960 shares during the last quarter. State Street Corp lifted its stake in shares of MaxCyte by 5.1% in the 3rd quarter. State Street Corp now owns 2,269,135 shares of the company’s stock worth $8,827,000 after acquiring an additional 111,066 shares during the period. ArrowMark Colorado Holdings LLC boosted its holdings in shares of MaxCyte by 13.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock valued at $5,426,000 after acquiring an additional 169,250 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC increased its stake in shares of MaxCyte by 0.6% during the fourth quarter. Chevy Chase Trust Holdings LLC now owns 1,339,829 shares of the company’s stock worth $5,574,000 after acquiring an additional 7,781 shares during the period. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Stock Down 3.2 %

NASDAQ:MXCT opened at $2.73 on Friday. MaxCyte, Inc. has a fifty-two week low of $2.70 and a fifty-two week high of $5.26. The firm’s fifty day simple moving average is $3.85 and its 200-day simple moving average is $3.90. The stock has a market cap of $289.46 million, a PE ratio of -8.03 and a beta of 1.35.

Analysts Set New Price Targets

MXCT has been the subject of a number of recent analyst reports. Stifel Nicolaus reduced their price objective on shares of MaxCyte from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 price target on MaxCyte and gave the company a “buy” rating in a report on Wednesday, March 12th.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.